December 2020. Volume 16. Number 4

Palivizumab in premature infants with a gestational age less than 29 weeks does not affect respiratory outcomes in adolescence

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Amitai N, Stafler P, Blau H, Kaplan E, Mussaffi H, Levine H, et al. Palivizumab Following Extremely Premature Birth Does Not Affect Pulmonary Outcomes in Adolescence [published online ahead of print, 2020 Apr 13]. Chest. 2020;168:660-9.

Reviewers: De Manuel Gómez C1, Gimeno Díaz de Atauri Á2.
1Servicio de Pediatría. Hospital Universitario La Paz. Madrid. España.
2Servicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: Cristina De Manuel Gómez . Email: cristina6490@gmail.com
Reception date: 20/09/2020
Acceptance date: 12/10/2020
Publication date: 04/11/2020

Abstract

Authors’ conclusions: palivizumab did not provide any discernible long-term protective effect. In adolescent survivors of extreme prematurity good clinical and physiological respiratory outcomes were shown, as well as improvement with respect to preschool age. The forced expiratory volume in the first second (FEV1) remained lower than in healthy subjects, although within the normal range.

Reviewers’ commentary: within its possible limitations, this study did not find any relevant clinical differences in adolescence between preterm infants who received palivizumab compared to those who did not. This data adds to the existing controversy regarding its use due to the high cost of the drug in relation to the benefits, which, according to the results of this study, do not seem to extend beyond school age.

How to cite this article

De Manuel Gómez C, Gimeno Díaz de Atauri A. En prematuros con edad gestacional menor de 29 semanas. el palivizumab no mejora los resultados de salud respiratoria en la adolescencia. Evid Pediatr. 2020;16:47.

AVC | Critically appraised articles

Amitai N, Stafler P, Blau H, Kaplan E, Mussaffi H, Levine H, et al. Palivizumab Following Extremely Premature Birth Does Not Affect Pulmonary Outcomes in Adolescence [published online ahead of print, 2020 Apr 13]. Chest. 2020;168:660-9.

Reviewers: De Manuel Gómez C1, Gimeno Díaz de Atauri Á2.
1Servicio de Pediatría. Hospital Universitario La Paz. Madrid. España.
2Servicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.
Correspondence: Cristina De Manuel Gómez . Email: cristina6490@gmail.com
Reception date: 20/09/2020
Acceptance date: 12/10/2020
Publication date: 04/11/2020

How to cite this article

De Manuel Gómez C, Gimeno Díaz de Atauri A. En prematuros con edad gestacional menor de 29 semanas. el palivizumab no mejora los resultados de salud respiratoria en la adolescencia. Evid Pediatr. 2020;16:47.

04/11/2020

Linked Comment